

# 1                    **Saliva Is Comparable to Nasopharyngeal Swabs** 2                    **for Molecular Detection of SARS-CoV-2**

3                    Cody Callahan<sup>a,b</sup>, Sarah Ditelberg<sup>b</sup>, Sanjucta Dutta<sup>b</sup>, Nancy Littlehale<sup>d</sup>, Annie Cheng<sup>b</sup>,  
4                    Kristin Kupczewski<sup>b</sup>, Danielle McVay<sup>b</sup>, Stefan Riedel<sup>b,d,e</sup>, James E. Kirby<sup>b,d,e</sup>,  
5                    and Ramy Arnaout<sup>b,c,d,e,#</sup>

6                    <sup>a</sup>Department of Radiology, <sup>b</sup>Department of Pathology, <sup>c</sup>Division of Clinical Informatics,  
7                    Department of Medicine, <sup>d</sup>Beth Israel Deaconess Medical Center, Boston, MA, 02215 USA;  
8                    <sup>e</sup>Harvard Medical School, Boston, MA, 02215 USA, <sup>f</sup>Abbott Laboratories, Abbott Park, IL,  
9                    60064, USA.

10                    #To whom correspondence should be addressed at

11                    Ramy Arnaout, MD, DPhil

12                    Beth Israel Deaconess Medical Center

13                    330 Brookline Avenue—YA309

14                    Boston, MA 02215

15                    [rarnaout@bidmc.harvard.edu](mailto:rarnaout@bidmc.harvard.edu)

16                    617-667-3648

17                    **Running Title:** Saliva for Detection of SARS-CoV-2

18                    **Keywords:** SARS-CoV-2, COVID-19, saliva, NP swab, limit of detection

19                    **Key points:** Saliva has comparable sensitivity and specificity to nasopharyngeal swabs for RT-  
20                    PCR-based COVID-19 testing (concordance,  $\kappa=0.93$ ;  $n=385$  participants), albeit with slightly  
21                    lower recovery of viral RNA. Treatment with a readily available guanidinium preservative within  
22                    24 hours of sample collection improves recovery.

23 **Abstract**

24 **Background.** The continued need for molecular testing for SARS-CoV-2 and potential for self-  
25 collected saliva as an alternative to nasopharyngeal (NP) swabs for sample acquisition led us to  
26 compare saliva to NP swabs in an outpatient setting, without restrictions to avoid food, drink,  
27 smoking, or tooth-brushing.

28 **Methods.** A total of 385 pairs of NP and saliva specimens were obtained, the majority from  
29 individuals presenting for initial evaluation, and were tested on two high-sensitivity RT-PCR  
30 platforms: the Abbott m2000 and Abbott Alinity m (both with limits of detection [LoD] of 100  
31 copies of viral RNA/mL).

32 **Results.** Concordance between saliva and NP was excellent overall (Cohen's  $\kappa=0.93$ ), for both  
33 initial and followup testing, for both platforms, and for specimens treated with guanidinium  
34 transport medium as preservative as well as for untreated saliva ( $\kappa=0.88-0.95$ ). Viral loads were  
35 on average 16x higher in NP specimens than saliva specimens, suggesting that only the  
36 relatively small fraction of outpatients (~8% in this study) who present with very low viral loads  
37 (<1,600 copies/mL from NP swabs) would be missed by testing saliva instead of NP swabs,  
38 when using sensitive testing platforms. Special attention was necessary to ensure leak-resistant  
39 specimen collection and transport.

40 **Conclusions.** The advantages of self-collection of saliva, without behavioral restrictions, will  
41 likely outweigh a minor potential decrease in clinical sensitivity in individuals less likely to pose  
42 an infectious risk to others for many real-world scenarios, especially for initial testing.

## 43 **Introduction**

44 The currently accepted gold-standard method for diagnosing infection with SARS-CoV-2 is  
45 performing RT-PCR on nasopharyngeal (NP) secretions collected using an NP swab. This is  
46 choice is consistent with and was in part based on experience with other respiratory pathogens  
47 such as influenza viruses. However, this nasopharynx has the drawback of requiring  
48 experienced healthcare staff to perform sample collection, and such personnel are in chronic  
49 short supply. Also, requiring potentially infectious patients to congregate at a collection site is  
50 not ideal as it may inadvertently lead to iatrogenic infection. These suboptimalities have led to a  
51 number of investigations into whether and under what clinical circumstances alternative  
52 specimen types might be able to substitute for NP swabs [1–12]. Nasal secretions have the  
53 advantage of being able to be self-collected by swabbing the anterior nares; however, nasal  
54 secretions been shown to be less sensitive than NP secretions for viral loads below ~1,000  
55 copies/mL [5,6,13] and still require a swab for collection (swabs have been in intermittently short  
56 supply over the course of the pandemic) [14].

57 Saliva has the advantage of requiring neither trained personnel nor a swab, making it an  
58 attractive alternative to both NP- and/or nasal-swab testing. Saliva can be self-collected using  
59 only a sterile container, making it amenable to at-home/off-site collection. Sensitive detection of  
60 respiratory viruses from saliva had been shown prior to the pandemic. [15,16]. Consequently,  
61 saliva has been the subject of a number of studies in the context of the pandemic; however,  
62 these have reached varying conclusions regarding the suitability of saliva as an alternative to  
63 NP swabs, with some studies showing complete concordance and others only moderate  
64 agreement [9]. Known and potential reasons for these differences include timing/acuity of  
65 patients' clinical presentation, storage/processing conditions of collected samples, and  
66 sensitivity of the respective testing platforms used for detection of SARS-CoV-2. To address  
67 these issues, we compared saliva to NP swabs in 1,600 subjects across two testing platforms  
68 (Abbott m2000 and Abbott Alinity m) and two sample-processing approaches (untreated/"neat"  
69 and treated with guanidinium as a preservative) for individuals presenting for initial presentation  
70 vs. followup testing.

## 71 **Methods**

72 **Institutional review.** This study was reviewed and approved by institutional review board at the  
73 Beth Israel Deaconess Medical Center (BIDMC; IRB protocol no. 2020P000769).

74 **Trial design.** This was a multi-arm study: initial vs. followup presentation, two different testing  
75 platforms (Abbott m2000 and Abbott Alinity m), and two different sample-processing pipelines  
76 for the saliva samples (unadulterated/“neat” saliva vs. preserved (“treated”) with guanidinium  
77 isothiocyanate [GITC], i.e. Abbott multi-collect transport media, part of the Abbott Multi-Collect  
78 Specimen Collection Kit, catalog no. 09K12-004; Abbott Laboratories, Abbott Park, IL). See Fig.  
79 1.

80 **Trial participants and sample collection.** Informed consent was obtained from English-  
81 speaking adults presenting for either initial or followup testing for COVID-19 at BIDMC and Beth  
82 Israel Deaconess Chelsea drive-through collection sites.

83 *Saliva specimens.* While waiting in line for NP testing, each participant was given a sterile  
84 sample collection cup (VWR International, part no. 76299-868) and asked to spit/drool to a  
85 clearly labeled 3mL fill line. No exclusions were made on the basis of recent consumption of  
86 food or drink or of smoking, and participants were not asked to rinse the mouth or perform any  
87 other preparation ahead of sample collection. They were informed that 3mL is a large amount of  
88 saliva and may take several minutes/deposits to achieve, and told that thinking of a favorite food  
89 may help trigger salivation. They were told to close the cup tightly when finished and to hand it  
90 to the healthcare worker who would be acquiring the NP specimen.

91 *NP specimens.* NP specimens were collected per standard protocol. Briefly, the NP swab was  
92 inserted into the nasopharynx and rotated for 10 seconds, removed, and placed in a vial  
93 containing viral transport media [17].

94 *Transport.* Saliva specimens were individually bagged and transported together with the NP  
95 specimen via courier to BIDMC’s central laboratory for testing. Courier frequency was every 1-  
96 2.5 hours, with the maximum transport time to the laboratory being approximately 20 minutes.  
97 Specimens were transported at room temperature. At the BIDMC Pathology central laboratory,  
98 specimens were logged in and processed for testing as described below.

99 **Sample processing.** For GITC-treated saliva samples, 1mL of saliva was added to the multi-  
100 Collect tube that contains 1.25mL GITC buffer (“treated”). For untreated saliva samples, 1mL  
101 was used “neat.” Samples with <1mL were excluded.

102 At the start of the study, treated, untreated, and a 1mL aliquot of NP sample from the same  
103 participant were briefly vortexed (2-5 seconds) and amplified using Abbott m2000 RealTime

104 SARS-CoV-2 Assay on an Abbott m2000 RealTime System or the Abbott Alinity m system. After  
105 16 positive untreated specimens were analyzed on the m2000, the untreated arm was  
106 abandoned in favor of the treated arm. Thereafter, treated specimens were stored at 4°C until  
107 the paired NP sample had resulted. If the NP sample was positive, the GITC sample was run  
108 alongside an additional 1mL aliquot from the NP sample. Categorical (positive vs. negative), Ct,  
109 and IC values were recorded. Cutoff for positive was a Ct value of 31.5 on the m2000 and 42 on  
110 the Alinity m.

111 **Limits of detection (LoD).** *NP.* The LoD for SARS-CoV-2 from NP swabs was validated at 100  
112 copies/mL on both the m2000 and Alinity m platforms, as described previously [18].

113 *Saliva.* To determine the LOD for saliva, a (non-infectious) recombinant, enveloped, positive-  
114 single-stranded RNA virus containing SARS-CoV-2 RNA (AccuPlex COVID-19, Seracare,  
115 Milford, MA, USA;  $1.3 \times 10^7$  copies/mL as determined by digital PCR) was initially diluted into  
116 RNA Storage Solution, purchased from Invitrogen (AM7001; ThermoFisher Scientific, Waltham,  
117 MA, USA) to make a positive stock. The positive stock was then spiked to target concentrations  
118 in pooled negative saliva prepared with purchased leftover remnant deidentified specimens. A  
119 portion of these spiked “neat” or “untreated” samples were combined with transport medium  
120 using a saliva: GITC volume ratio of 1:1.25; these are “treated” samples. Tested concentrations  
121 were 900, 675, 450, 225, and 112.5 copies/mL for untreated samples and 400, 300, 200, 100,  
122 and 50 copies/mL for treated samples. The initial LoD was determined by testing targeted levels  
123 in replicates of 3; the final LoD was confirmed by testing in 21 additional replicates of the lowest  
124 two dilutions.

125 **Stability testing.** Saliva specimens were collected as described above and stored at 4°C  
126 pending results of the paired NP specimen. Twenty NP-confirmed negative saliva specimens  
127 were pooled. The pooled sample was spiked to a final concentration of 11,215 copies/mL of  
128 SeraCare material and aliquotted into  $24 \times 1.1$  mL replicates. Starting immediately (the 0-hour  
129 timepoint), each of three replicates was treated with 1.2mL GITC and promptly run on the Alinity  
130 m platform per standard protocol. This was repeated at 4, 8, 12, 16, 20, 24, and 45 hours.  
131 Replicates were stored at room temperature between time points. Categorical, Ct, and IC values  
132 were recorded.

133 **Sample-processing times.** NP specimens were tracked using BIDMC’s clinical data system,  
134 with the following recorded: order creation time as a surrogate for sample collection time ( $\pm 15$

135 minutes), lab-control time (sample login at BIDMC), login time at BIDMC's molecular diagnostics  
136 laboratory, archive time, and result time.

137 **Statistical analyses.** For concordance testing, RT-PCR results were considered categorically  
138 as either positive or negative; testing agreement was assessed by Cohen's kappa ( $\kappa$ ) [19].  
139 Conversion to viral load was performed as described previously [20]. "Initial testing" was defined  
140 as testing of a saliva sample collected fewer than five days after the first COVID-19 RT-PCR  
141 test. "Followup testing" was defined as testing occurring thereafter. Leaking samples and  
142 internal-control failures were omitted from analysis.

143 **Significance testing.** We tested whether Ct values for a given subset of saliva samples differed  
144 from the Ct values for the paired NP swabs (the controls) using Wilcoxon's signed rank test.  
145 This tested the null hypothesis that values for controls and prototypes are drawn from the same  
146 underlying distribution. The Benjamini-Hochberg approach [21] was used to control the false-  
147 discovery rate (FDR) at 1%.

148 **Software.** We used Python (v3.6-3.8) and its NumPy, SciPy, Matplotlib, Pandas, and ct2vl  
149 libraries for the above analyses and related visualizations.

150 **Data Availability.** De-identified data is presented in Supplementary File 1. Supplementary Data  
151 can be found at ([https://github.com/rarnaout/Covid\\_diagnostics](https://github.com/rarnaout/Covid_diagnostics)).

## 152 **Results**

153 *Study design and overall observations.* Figure 1 depicts the design of this study of adults being  
154 tested by RT-PCR for infection with SARS-CoV-2 and the numbers of participants tested in  
155 each arm. Participants waiting for NP sample collection were asked to spit into a sterile urine  
156 cup clearly marked with a 3-mL fill line until the line was reached. Participants were informed  
157 that this would likely require spitting more than once, encouraged to persist despite any  
158 embarrassment or distaste/mild disgust, and instructed to thread the lids carefully and close  
159 them tightly to avoid leaking. Study staff retightened cups as necessary. Saliva specimens were  
160 double bagged and shipped alongside the NP specimen. Overall, this limited the incidence of  
161 leaking saliva, which was encountered frequently initially.

162 *Limit of detection of SARS-CoV-2 in saliva on Abbott m2000 and Alinity m.* In spiking  
163 experiments, the lowest concentration level with observed positive rates  $\geq 95\%$  was 100  
164 copies/mL in treated saliva and 225 copies/mL in untreated saliva. Logistic regression estimated

165 LoDs of 45 copies/mL in treated and 104 copies/mL in untreated saliva (76 copies/mL  
166 combined), statistically comparable to the previously validated LoD for NP swabs on these  
167 platforms, 100 copies/mL (Fig. 2). (Note that treatment results in a roughly 2-fold dilution of the  
168 sample.)

169 *Stability of SARS-CoV-2 in saliva over time.* Replication-incompetent, enveloped, positive  
170 single-stranded RNA Sindbis virus into which SARS-CoV-2 genomic material was cloned as a  
171 non-infectious SARS-CoV-2 surrogate was stable in untreated saliva at room temperature, with  
172 concentration falling by ~3 fold within the first four hours but then staying stable at that level  
173 through two days (Fig. 3). Saliva treated with the preservative GITC was stable for at least 24  
174 hours. Together, these findings support the viability of workflows in which, as a limiting timeline,  
175 saliva is collected and transported “neat” and treated with GITC within two days for subsequent  
176 testing.

177 *Comparison of saliva to NP swabs.* Overall, saliva results were highly concordant (Cohen’s  
178  $\kappa=0.93$ ) with results from paired NP swabs obtained from participants in a medium-to-high  
179 prevalence population (~20% positivity) who presented for screening and follow-up, as tested on  
180 two sensitive RT-PCR platforms, the Abbott Alinity m and Abbott m2000 (LoD 100 copies/mL)  
181 (Fig. 4). Using the LoD as the cutoff, there were only nine discordant results among 385 paired  
182 samples, and these were evenly balanced (4 NP-swab-positive/saliva-negative samples vs. 5  
183 saliva-positive/NP-swab-negative samples). Despite the high concordance, (geometric) mean  
184 viral load in NP samples was ~16 times as high as in saliva samples (3.1 million vs. 200,000  
185 copies/mL, respectively; Wilcoxon  $p$  value for difference of saliva vs. NP viral load distributions,  
186  $2 \times 10^{-6}$ ). These trends were robust across all subgroups analyzed, whether by initial testing  
187 ( $n=343$ ,  $\kappa=0.93$ ) or follow-up testing ( $n=42$ ,  $\kappa=0.88$ ); whether samples were treated with GITC as  
188 soon as they reached the laboratory (Fig. 5) ( $n=316$ ,  $\kappa=0.92$ ) or not ( $n=69$ ,  $\kappa=0.95$ ); and whether  
189 they were run on the Alinity m ( $n=207$ ,  $\kappa=0.91$ ) or m2000 ( $n=178$ ,  $\kappa=0.94$ ). Notably, mean viral  
190 load for NP-swab samples was 13 times as high as for saliva samples treated with GITC vs. 40  
191 times as high for untreated saliva samples. Mean viral load was 2-3x as high for participants  
192 presenting for their initial COVID-19 test vs. follow-up (3.7 million vs. 1.5 million copies/mL,  
193 respectively, as measured on NP samples, and 240,000 vs. 81,000 copies/mL, respectively, as  
194 measured on saliva samples).

## 195 **Discussion**



196 While saliva testing has shown promise as a suitable specimen for detection of several viral  
197 respiratory pathogens [8–10,15], NP swabs remain the gold standard in most clinical settings,  
198 requiring well-trained healthcare staff to obtain them. The demands of the COVID-19 pandemic  
199 have led to a number of investigations of saliva for molecular detection of SARS-CoV-2 in a  
200 wide range of clinical and non-clinical settings and with a variety of patient instructions and  
201 processing steps, with the overall conclusion that saliva is comparable to but slightly inferior to  
202 NP swabs [22]. Some studies have instructed patients to provide morning specimens or to  
203 abstain from eating/drinking/smoking before providing a specimen, constraints that complicate  
204 collection. We sought to test how well saliva testing in a real-world outpatient setting without any  
205 such constraints would perform, with the only special handling step being adding a preservative,  
206 in the form of GITC transport buffer once the specimen arrived from the outpatient site to our  
207 hospital's central laboratory for testing.

208 The overall results in our current study were consistent with previous work [22], with very high  
209 concordance between saliva and NP swabs under all scenarios tested. A minor but surprisingly  
210 important observation was the importance of leak-resistant collection cups, as a substantial  
211 number of collected specimens were unusable due to leaks, despite proper instruction for  
212 sample collection. The leak-resistant cups we adopted mitigated leaking somewhat, as they  
213 incorporated a soft gasket-like seal inside the lid, with a thread length to pitch ratio of ~3. Cups  
214 using a more deformable gasket or larger ratio may further reduce sample leakage.  
215 Nevertheless, our experience demonstrates that simple and readily available specimen-  
216 collection cups can be repurposed for saliva collection for respiratory-virus testing. Usefully, we  
217 observed high concordance without any restrictions on participant activities  
218 (eating/drinking/smoking/tooth brushing; the color and heterogeneity of several saliva samples  
219 was highly suggestive of these activities); without asking participants to rinse, cough, or retch;  
220 and without requiring specimens to be obtained in the morning (indeed most of samples were  
221 collected in the early afternoon). While it cannot be ruled out that these additional requirements  
222 might improve performance (~5% improvement in concordance in meta-analysis (20)), the  
223 results of the present study suggest that the procedural hurdles of obtaining specimens with  
224 these constraints likely outweigh any modest incremental benefit.

225 Furthermore, we demonstrated that SARS-CoV-2 viral material was stable in GITC-treated  
226 saliva for at least 24 hours. The time between sample collection and addition of GITC never  
227 exceeded 12 hours. Treatment was performed in the laboratory and not earlier, at the collection  
228 site, for simplicity of workflow. We chose not to include the preservative in the specimen-



229 collection cups for concern over potential exposure of participants to a caustic substance. The  
230 median time between specimen collection and addition of GITC was approximately 6 hours (Fig.  
231 5); however, we demonstrated that viral material is fairly stable in saliva at room temperature  
232 without preservative, retaining approximately half of viral load at 24 hours and a third at 45  
233 hours, allowing room-temperature transport and login times of over a day. Consistent with these  
234 stability studies, untreated saliva samples showed indistinguishably high concordance with NP  
235 swabs compared to GITC-treated saliva samples (Fig. 4d-e), although the mean viral load in  
236 untreated samples was approximately 3x lower (also consistent with stability studies).

237 Despite the high concordance overall ( $\kappa=0.93$ ) and for all subgroup analyses ( $\kappa=0.88-0.95$ ),  
238 including for participants presenting for follow-up as well as during initial presentation, the on-  
239 average 13x higher viral load detected by NP swabs vs. paired GITC-treated saliva specimens  
240 deserves mention. Provided that viral load (as measured by NP swab) is greater than 13 times  
241 the platform's LoD (100 copies/mL in our study), saliva treated with GITC within 24 hours of  
242 collection is highly likely to detect infection. However, viral loads less than this threshold (1,300  
243 copies/mL) may be missed. In our study, approximately 92% of initial presentations were above  
244 this threshold. The analogous ratio for untreated saliva was 40x, corresponding to a threshold of  
245 4,000 copies/mL; approximately 90% of initial presentations were above this threshold. We  
246 conclude that saliva can be fairly expected to detect over 90% of initial SARS-CoV-2 infections  
247 in an outpatient setting. To the extent that more severe disease correlates with higher viral  
248 loads, performance in inpatient settings is likely to be even higher. Furthermore, a detection  
249 level in saliva that would correspond to 4,000 copies/mL in NP swab samples is likely to capture  
250 those who are infectious and is also likely significantly below the limit of detection of currently  
251 marketed SARS-CoV-2 antigen tests [20].

252 In conclusion, we have demonstrated that saliva is comparable to NP-swab collection for  
253 molecular detection of SARS-CoV-2 in an outpatient setting, with the disadvantage of slightly  
254 lower viral loads. This loss in sensitivity must be weighed against the ease of self-collection.  
255 However, we have demonstrated that use of saliva for SARS-CoV-2 molecular detection is both  
256 feasible and practical, given suitable specimen-collection containers and transport and  
257 processing protocols.


258 **Acknowledgements**

259 The authors gratefully acknowledge the participation of patients and staff at Beth Israel  
260 Deaconess Healthcare | Chelsea for making this study possible. We also acknowledge critical  
261 reading of the manuscript, as well as study design input by Joshua Kostera.


262 **Potential conflicts of interest**

263 This work was supported through a sponsored research agreement with Abbott Molecular. CC,  
264 SD, SD, NL, AC, KK, DM, SR, and RA have no other potential conflicts of interest to declare. JK  
265 has received reagents from Abbott Molecular for unrelated studies under a Covid-19  
266 Diagnostics Evaluation Agreement.


267 **Figures**




268 **Figure 1.** Numbers of participants in each study arm.




269 **Figure 2.** LoD for treated and untreated saliva on Abbott m2000 and Alinity m platforms. Lowest  
270 two datapoints, 24 replicates each; others in triplicate.



271 **Figure 3.** Stability of replication-incompetent SARS-CoV-2 surrogate virus in untreated saliva  
272 samples over time. Triplicate measurements in gray; geometric means in black.



273 **Figure 4.** Viral load in saliva vs. NP swab samples, Cohen's kappa ( $\kappa$ ) concordance values, and  
 274 contingency tables for (a) overall study, (b) subjects presenting for initial presentation (within 5  
 275 days of first COVID-19 RT-PCR test), (c) subjects presenting for followup testing, (d) samples  
 276 treated with GTC transport buffer as a preservative after receipt at the central laboratory, (e)  
 277 untreated samples, (f) samples run on the Alinity m platform, and (g) samples run on the  
 278 m2000. Diagonal lines in scatterplots, 1:1. Gray shaded areas in the scatterplots are below the  
 279 LoD (100 copies/mL). Gray shaded cells in the contingency tables highlight discordant results.



280 **Figure 5.** Sample processing times, ranked by increasing order of total time. Sample-to-login  
281 time is the time between sample acquisition and login at the central laboratory. Login-to-  
282 processing time is the time between login and arrival of the specimen in the molecular  
283 laboratory where GITC treatment and RT-PCR testing are performed.



## 284 References

1. LeBlanc JJ, Heinstein C, MacDonald J, Pettipas J, Hatchette TF, Patriquin G. A combined oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of SARS-CoV-2. *Journal of Clinical Virology* **2020**; 128:104442.
2. Rhoads DD, Cherian SS, Roman K, Stempak LM, Schmotzer CL, Sadri N. Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19. *J Clin Microbiol* **2020**; :JCM.00760-20, jcm;JCM.00760-20v1.
3. McCormick-Baw C, Morgan K, Gaffney D, et al. Saliva as an Alternate Specimen Source for Detection of SARS-CoV-2 in Symptomatic Patients Using Cepheid Xpert Xpress SARS-CoV-2. *J Clin Microbiol* **2020**; :JCM.01109-20, jcm;JCM.01109-20v1.
4. Kojima N, Turner F, Slepnev V, et al. Self-Collected Oral Fluid and Nasal Swabs Demonstrate Comparable Sensitivity to Clinician Collected Nasopharyngeal Swabs for Covid-19 Detection. *medRxiv* **2020**; :2020.04.11.20062372.
5. Berenger BM, Fonseca K, Schneider AR, Hu J, Zelyas N. Sensitivity of Nasopharyngeal, Nasal and Throat Swab for the Detection of SARS-CoV-2. *medRxiv* **2020**; :2020.05.05.20084889.
6. Callahan C, Lee RA, Lee GR, Zulauf K, Kirby JE, Arnaout R. Nasal-Swab Testing Misses Patients with Low SARS-CoV-2 Viral Loads. *medRxiv* **2020**; :2020.06.12.20128736.
7. Azzi L, Carcano G, Gianfagna F, et al. Saliva is a reliable tool to detect SARS-CoV-2. *Journal of Infection* **2020**; 81:e45–e50.
8. Griesemer SB, Van Slyke G, Ehrbar D, et al. Evaluation of specimen types and saliva stabilization solutions for SARS-CoV-2 testing. *medRxiv*
9. Nagura-Ikeda M, Imai K, Tabata S, et al. Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription–Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19. *J Clin Microbiol* **2020**; 58:e01438-20, /jcm/58/9/JCM.01438-20.atom.

10. Ranoa DRE, Holland RL, Alnaji FG, et al. Saliva-Based Molecular Testing for SARS-CoV-2 that Bypasses RNA Extraction. *Microbiology*, 2020. Available at: <http://biorxiv.org/lookup/doi/10.1101/2020.06.18.159434>. Accessed 19 March 2021.
11. Teo AKJ, Choudhury Y, Tan IB, et al. Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection. *Sci Rep* **2021**; 11:3134.
12. Tu Y, Jennings R, Hart B, et al. Patient-collected tongue, nasal, and mid-turbinate swabs for SARS-CoV-2 yield equivalent sensitivity to health care worker collected nasopharyngeal swabs. *Infectious Diseases (except HIV/AIDS)*, 2020. Available at: <http://medrxiv.org/lookup/doi/10.1101/2020.04.01.20050005>. Accessed 19 March 2021.
13. Péré H, Podglajen I, Wack M, et al. Nasal Swab Sampling for SARS-CoV-2: a Convenient Alternative in Times of Nasopharyngeal Swab Shortage. *J Clin Microbiol* **2020**; 58:e00721-20, [/jcm/58/6/JCM.00721-20.atom](https://doi.org/10.1128/JCM.00721-20).
14. Callahan CJ, Lee R, Zulauf KE, et al. Open Development and Clinical Validation of Multiple 3D-Printed Nasopharyngeal Collection Swabs: Rapid Resolution of a Critical COVID-19 Testing Bottleneck. *Journal of Clinical Microbiology* **2020**; 58. Available at: <https://jcm.asm.org/content/58/8/e00876-20>. Accessed 17 December 2020.
15. To KKW, Yip CCY, Lai CYW, et al. Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study. *Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases*
16. To KK, Lu L, Yip CC, et al. Additional molecular testing of saliva specimens improves the detection of respiratory viruses. *Emerging Microbes & Infections* **2017**; 6:1–7.
17. Smith KP, Cheng A, Chopelas A, et al. Large-scale, in-house production of viral transport media to support SARS-CoV-2 PCR testing in a multi-hospital healthcare network during the COVID-19 pandemic. *Journal of Clinical Microbiology* **2020**; Available at: <https://jcm.asm.org/content/early/2020/05/11/JCM.00913-20>. Accessed 10 June 2020.

18. Arnaout R, Lee RA, Lee GR, et al. The Limit of Detection Matters: The Case for Benchmarking Severe Acute Respiratory Syndrome Coronavirus 2 Testing. *Clin Infect Dis* **2021**;
19. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb)* **2012**; 22:276–282.
20. Arnaout R, Lee RA, Lee GR, et al. The Limit of Detection Matters: The Case for Benchmarking Severe Acute Respiratory Syndrome Coronavirus 2 Testing. *Clin Infect Dis* **2021**;
21. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B (Methodological)* **1995**; 57:289–300.
22. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of Saliva, Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: A Systematic Review and Meta-analysis. *Journal of Clinical Microbiology* **2021**; Available at: <https://jcm.asm.org/content/early/2021/01/26/JCM.02881-20>. Accessed 29 March 2021.